Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.55 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485648 | 0.86 | CYP1A2 (0.59) | CYP1A2CYP2A6IDO1EP300KAT8 | |
| SCHEMBL29380721 | 0.85 | IDO1 (0.73) | IDO1EP300KAT8TSHRIMPDH2 | |
| SCHEMBL419307 | 0.85 | IDO1 (0.73) | IDO1EP300KAT8TSHRIMPDH2 | |
| SCHEMBL13019803 | 0.78 | CYP1A2 (0.54) | CYP1A2CYP2A6TSHRNPC1RAB9A | |
| SCHEMBL12019841 | 0.78 | IDO1 (0.64) | IDO1EP300KAT8IMPDH2IMPDH1 | |
| SCHEMBL31666411 | 0.78 | IDO1 (0.64) | CYP1A2IDO1EP300KAT8IMPDH2 | |
| SCHEMBL7753164 | 0.78 | IDO1 (0.64) | IDO1EP300KAT8IMPDH2IMPDH1 | |
| SCHEMBL12019777 | 0.78 | IDO1 (0.64) | IDO1EP300KAT8IMPDH2IMPDH1 | |
| SCHEMBL10963495 | 0.78 | ESRRA (0.46) | CYP1A2CYP2A6IDO1EP300KAT8 | |
| SCHEMBL3751527 | 0.77 | CYP1A2 (0.59) | CYP1A2CYP2A6TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| US-8357806-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-30 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100093747-A1 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS | CELTAXSYS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7365082-B2 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | BAYER CROPSCIENCE AG (DE) | 2008-04-29 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1572668-A4 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20060166962-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | FMC CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1572668-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004060865-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| US-4298532-A | INTERMEDIATES FOR MICROBIOCIDES | RIKER LABORATORIES, INC. (US) | 1981-11-03 | — | — | US | disclosed |
| US-4260547-A | MICROBIOCIDES | RIKER LABORATORIES, INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4231965-A | CHEMICAL INTERMEDIATES FOR MICROBIOCIDES | RIKER LABORATORIES, INC. (US) | 1980-11-04 | — | — | US | disclosed |
| US-4154848-A | MICROBIOCIDES, BACTERICIDES | RIKER LABORATORIES, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4128659-A | 2-NITRO-3-PHENYL-BENZOFURANS | RIKER LABORATORIES, INC. (US) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | CYP1A2 26/4885CYP2A6 188/4885IDO1 437/4885 |
| US-20100093747-A1 | METHOD OF INDUCING NEGATIVE CHEMOTAXIS | PMAIP1, CDC42, DCX | CYP1A2 4827/4885CYP2A6 4687/4885IDO1 4633/4885 |
| US-20060166962-A1 | N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines | DDT, DRD4, DRD1 | CYP1A2 927/4885CYP2A6 1697/4885IDO1 1982/4885 |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | CYP1A2 26/4885CYP2A6 188/4885IDO1 437/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | CYP1A2 20/4885CYP2A6 286/4885IDO1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.